PROCUREMENT PLAN (Textual Part)

Project information: Egypt Transforming Egypt's Healthcare System Project P167000

Project Implementation agency: Ministry of Health and Population

Date of the Procurement Plan: October 23, 2018

Period covered by this Procurement Plan: 18 months

Preamble

In accordance with paragraph 5.9 of the “World Bank Procurement Regulations for IPF Borrowers” (July 2016) (“Procurement Regulations”) the Bank’s Systematic Tracking and Exchanges in Procurement (STEP) system will be used to prepare, clear and update Procurement Plans and conduct all procurement transactions for the Project.

This textual part along with the Procurement Plan tables in STEP constitute the Procurement Plan for the Project. The following conditions apply to all procurement activities in the Procurement Plan. The other elements of the Procurement Plan as required under paragraph 4.4 of the Procurement Regulations are set forth in STEP.

The Bank’s Standard Procurement Documents: shall be used for all contracts subject to international competitive procurement and those contracts as specified in the Procurement Plan tables in STEP.

National Procurement Arrangements: In accordance with paragraph 5.3 of the Procurement Regulations, when approaching the national market (as specified in the Procurement Plan tables in STEP), the country’s own procurement procedures may be used.

Leased Assets: “Not Applicable”

Procurement of Second Hand Goods: “Not Applicable”

Domestic preference as specified under paragraph 5.51 of the Procurement Regulations (Goods and Works).

Goods: is applicable for those contracts identified in the Procurement Plan tables;

Other Relevant Procurement Information.

NA
| Work Package | Work Type | Activity | Activity No. | Component | DP Code | Oper | Proc | PO | PO Code | Contract Date | Contract Value | Contract Value | QA Control | Quality Control | Completion Date | Impact | Usage | Amount | Impact | Usage | Amount |
|--------------|-----------|----------|--------------|-----------|---------|------|------|----|---------|--------------|----------------|----------------|-------------|--------------|----------------|----------------|-------|-------|--------|--------|-------|--------|
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
|              |           |          |              |           |         |      |      |    |         |              |                |                |             |              |                |        |       |        |        |       |        |
Daclatasvir
Sofosbuvir

National weeks

Daclatasvir Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasvir
Sofosbuvir

Daclatasv
<table>
<thead>
<tr>
<th>ID</th>
<th>Supplier</th>
<th>QUOTATION ERASURED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ABC Company</td>
<td>98.800.00</td>
</tr>
<tr>
<td>2</td>
<td>XYZ Corporation</td>
<td>97.800.00</td>
</tr>
<tr>
<td>3</td>
<td>MNO Industries</td>
<td>98.900.00</td>
</tr>
<tr>
<td>4</td>
<td>PQR Enterprises</td>
<td>98.850.00</td>
</tr>
<tr>
<td>5</td>
<td>STU Group</td>
<td>97.800.00</td>
</tr>
<tr>
<td>6</td>
<td>UVW Corporation</td>
<td>98.000.00</td>
</tr>
<tr>
<td>7</td>
<td>WXY Industries</td>
<td>98.108.37</td>
</tr>
<tr>
<td>8</td>
<td>ZYX Enterprises</td>
<td>97.581.41</td>
</tr>
<tr>
<td>9</td>
<td>ABC Company</td>
<td>98.308.20</td>
</tr>
<tr>
<td>10</td>
<td>XYZ Corporation</td>
<td>97.972.25</td>
</tr>
<tr>
<td>11</td>
<td>MNO Industries</td>
<td>97.190.56</td>
</tr>
<tr>
<td>12</td>
<td>PQR Enterprises</td>
<td>98.167.67</td>
</tr>
</tbody>
</table>

Signed: 2019-01-05
**Egyptian district.**

**Daclatasvir** through the **Egyptian medicines** the district. **Daclatasvir** through for **EG-MOHP-83616-GO-RFQ** and **EG-MOHP-83615-GO-RFQ** currently are national for **EG-MOHP-83571-GO-RFQ**.

**Sofosbuvir** are national for **EG-MOHP-83324-GO-RFQ**. Daclatasvir and **EG-MOHP-83309-GO-RFQ** are national through combination for **Sofosbuvir** are national for **EG-MOHP-83301-GO-RFQ**. Daclatasvir are through the weeks **EG-MOHP-83305-GO-RFQ**. **Daclatasvir** of **EG-MOHP-83301-GO-RFQ**.

**Management**:

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-11-25</td>
<td></td>
<td>97,700.00</td>
<td></td>
</tr>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,300.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,150.00</td>
<td></td>
</tr>
</tbody>
</table>

**Renewal**:

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-11-25</td>
<td></td>
<td>97,800.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,300.00</td>
<td></td>
</tr>
</tbody>
</table>

**Participation**:

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,000.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>97,800.00</td>
<td></td>
</tr>
</tbody>
</table>

**Envelope**:

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,300.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,363.09</td>
<td></td>
</tr>
</tbody>
</table>

**Signed**:

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-11-25</td>
<td></td>
<td>99,898.79</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,715.09</td>
<td></td>
</tr>
</tbody>
</table>

**Stage**:

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,116.56</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,116.56</td>
<td></td>
</tr>
</tbody>
</table>

**12 weeks**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-11-25</td>
<td></td>
<td>98,108.37</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,108.37</td>
<td></td>
</tr>
</tbody>
</table>

**IBRD**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,000.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,108.37</td>
<td></td>
</tr>
</tbody>
</table>

**Secondary**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,000.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,108.37</td>
<td></td>
</tr>
</tbody>
</table>

**Strengthen**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-11-25</td>
<td></td>
<td>99,898.79</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,715.09</td>
<td></td>
</tr>
</tbody>
</table>

**Healthcare**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,116.56</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,116.56</td>
<td></td>
</tr>
</tbody>
</table>

**Envelopes**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-11-25</td>
<td></td>
<td>99,898.79</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,715.09</td>
<td></td>
</tr>
</tbody>
</table>

**IBRD**

<table>
<thead>
<tr>
<th>Date</th>
<th>Lot</th>
<th>Unit Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-10-06</td>
<td></td>
<td>98,000.00</td>
<td></td>
</tr>
<tr>
<td>2019-01-24</td>
<td></td>
<td>98,108.37</td>
<td></td>
</tr>
</tbody>
</table>
for combination treatment district.

EG-MOHP-83686-GO-RFQ

EG-MOHP-83678-GO-RFQ

EG-MOHP-83669-GO-RFQ

Purchasing currently weeks for hepatitis national of

Daclatasvir

Sofosbuvir

of

98,500.00

99,910.84

99,271.94

112,502.29

Signed

Limited Single Envelope Stage

2018-11-14

2018-11-24

2019-01-24

2018-11-25
<table>
<thead>
<tr>
<th>Date</th>
<th>Product</th>
<th>Quantity</th>
<th>Unit</th>
<th>Cost</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-12-29</td>
<td>EG-MOHP-92442-GO-RFQ</td>
<td>12000</td>
<td>mg</td>
<td>98,000.00</td>
<td>Signed</td>
</tr>
<tr>
<td>2018-12-28</td>
<td>EG-MOHP-92446-GO-RFQ</td>
<td>10000</td>
<td>mg</td>
<td>97,700.00</td>
<td>Stage</td>
</tr>
<tr>
<td>2018-12-27</td>
<td>EG-MOHP-88971-GO-RFQ</td>
<td>8000</td>
<td>mg</td>
<td>97,500.00</td>
<td>Stage</td>
</tr>
<tr>
<td>2019-01-05</td>
<td>EG-MOHP-88972-GO-RFQ</td>
<td>6000</td>
<td>mg</td>
<td>98,500.00</td>
<td>Stage</td>
</tr>
<tr>
<td>2019-01-06</td>
<td>EG-MOHP-88974-GO-RFQ</td>
<td>4000</td>
<td>mg</td>
<td>97,500.00</td>
<td>Stage</td>
</tr>
<tr>
<td>2019-01-11</td>
<td>EG-MOHP-92437-GO-RFQ</td>
<td>2000</td>
<td>mg</td>
<td>98,500.00</td>
<td>Stage</td>
</tr>
</tbody>
</table>

**Notes:**
- **Weeks:** Daclatasvir and Sofosbuvir are currently used for the treatment of the Egyptian virus in district. Elfatimia virus is used for the treatment of digestive fevers.
- **program:** The national program for Strengthening Healthcare implemented Secondary Stage - Post Quotations Request for One Single Envelope Limited Stage - 2018-12-28 to 2018-12-30.
<table>
<thead>
<tr>
<th>Month</th>
<th>Supplier</th>
<th>Unit</th>
<th>Item</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-12-29</td>
<td>Assiut</td>
<td>60</td>
<td>Sofosbuvir</td>
<td>400mg+</td>
<td>98,000.00</td>
</tr>
<tr>
<td>2019-01-06</td>
<td>Alexandria</td>
<td>12</td>
<td>Sofosbuvir</td>
<td>400mg+</td>
<td>98,300.00</td>
</tr>
<tr>
<td>2019-03-07</td>
<td>Benha</td>
<td>60</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>106,928.27</td>
</tr>
</tbody>
</table>

Note: The above table represents the quantities and prices for Sofosbuvir and Daclatasvir purchased for different months and regions.
<table>
<thead>
<tr>
<th>ID</th>
<th>Quantity</th>
<th>Unit</th>
<th>Price</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10</td>
<td>kg</td>
<td>98,000.00</td>
<td>Cairo</td>
</tr>
<tr>
<td>2</td>
<td>15</td>
<td>kg</td>
<td>98,000.00</td>
<td>Alexandria</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>kg</td>
<td>98,000.00</td>
<td>Assuit</td>
</tr>
</tbody>
</table>

*Note: All quantities are in kilograms.*
Insurance are national through Daclatasvir Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.

Daclatasvir / Sofosbuvir the combination currently being used for El virus treatment.
<table>
<thead>
<tr>
<th>Contract</th>
<th>Expected Date</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-92573-GO-RFQ</td>
<td>2018-12-29</td>
<td>0.00</td>
</tr>
<tr>
<td>EG-MOHP-92570-GO-RFQ</td>
<td>2018-12-29</td>
<td>0.00</td>
</tr>
<tr>
<td>EG-MOHP-92560-GO-RFQ</td>
<td>2018-12-29</td>
<td>0.00</td>
</tr>
<tr>
<td>EG-MOHP-92557-GO-RFQ</td>
<td>2018-12-29</td>
<td>0.00</td>
</tr>
<tr>
<td>EG-MOHP-92555-GO-RFQ</td>
<td>2018-12-29</td>
<td>0.00</td>
</tr>
<tr>
<td>EG-MOHP-92555-GO-RFQ</td>
<td>2019-01-06</td>
<td>0.00</td>
</tr>
<tr>
<td>EG-MOHP-92550-GO-RFQ</td>
<td>2019-03-07</td>
<td>0.00</td>
</tr>
</tbody>
</table>

---

**Clinic** current combination for National Insurance weeks.

**Clinic** currently used drugs.

**Clinic** of 12 mg for IBRD.

**Clinic** of 88950 bottles for IBRD.

**Clinic** of 98,300.00 for IBRD.

**Clinic** of 106,199.19 for IBRD.

**Clinic** of 106,392.63 for IBRD.

**Clinic** of 105,716.01 for IBRD.
<table>
<thead>
<tr>
<th>ID</th>
<th>Quantity</th>
<th>Unit</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-92612-GO-RFQ</td>
<td>60</td>
<td>weeks</td>
<td>98,100.00</td>
</tr>
<tr>
<td>EG-MOHP-92611-GO-RFQ</td>
<td>60</td>
<td>weeks</td>
<td>98,800.00</td>
</tr>
<tr>
<td>EG-MOHP-92608-GO-RFQ</td>
<td>60</td>
<td>weeks</td>
<td>98,300.00</td>
</tr>
<tr>
<td>EG-MOHP-92595-GO-RFQ</td>
<td>60</td>
<td>weeks</td>
<td>98,000.00</td>
</tr>
<tr>
<td>Purchasing El Sondepis Tadaman Healthcare</td>
<td>12</td>
<td>combination</td>
<td>108,578.50</td>
</tr>
<tr>
<td>Purchasing El Tahta Healthcare</td>
<td>12</td>
<td>combination</td>
<td>104,634.92</td>
</tr>
<tr>
<td>Purchasing Farskour Healthcare</td>
<td>12</td>
<td>combination</td>
<td>106,231.29</td>
</tr>
<tr>
<td>Purchasing Juhayna Healthcare</td>
<td>12</td>
<td>combination</td>
<td>98,500.00</td>
</tr>
<tr>
<td>Purchasing Balina Healthcare</td>
<td>12</td>
<td>combination</td>
<td>104,634.92</td>
</tr>
<tr>
<td>Purchasing</td>
<td>12</td>
<td>combination</td>
<td>98,300.00</td>
</tr>
</tbody>
</table>

Strengthen Level - Secondary Stage - Quotations Requested.

Signed 2019-01-05

Pending 2019-03-06

Signed 2019-03-07

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12

400mg+ 12
Daclatasvir and Sofosbuvir are national treatment drugs in Egypt. Sofosbuvir/400mg+ combination is currently being purchased for the Matamer El Qanatr, Matamer El Dabaa, and Matamer El Qena governorates. Daclatasvir and Sofosbuvir are also available for the Matamer El Matamer, Matamer El Asyut, and Matamer El Matamer governorates.

EG-MOHP-98999-GO-RFQ
EG-MOHP-93910-GO-RFQ
EG-MOHP-93907-GO-RFQ
EG-MOHP-92620-GO-RFQ
EG-MOHP-92618-GO-RFQ
EG-MOHP-92614-GO-RFQ

12 weeks of treatment is recommended for patients with HCV infection. Daclatasvir and Sofosbuvir are also available for the El Matamer, El Qena, and El Matamer governorates.

88950

IBRD Level Strengthen Activities Planning Healthcare, IBRD Level Strengthen Activities Planning Healthcare, and IBRD Level Strengthen Activities Planning Healthcare are also available for the Matamer El Matamer, Matamer El Asyut, and Matamer El Matamer governorates.
<table>
<thead>
<tr>
<th>Date</th>
<th>Contract Code</th>
<th>Description</th>
<th>Quantity</th>
<th>Unit</th>
<th>Price (1)</th>
<th>Price (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019-05-02</td>
<td>EG-MOHP-115163-GO-RFQ</td>
<td>Sofosbuvir for Qena district.</td>
<td>400mg+60mg</td>
<td>60c</td>
<td>98,700.00</td>
<td>106,185.32</td>
</tr>
<tr>
<td>2019-05-02</td>
<td>EG-MOHP-115169-GO-RFQ</td>
<td>Daclatasvir for Qena district.</td>
<td>400mg+60mg</td>
<td>60c</td>
<td>105,030.08</td>
<td>106,185.32</td>
</tr>
<tr>
<td>2019-05-02</td>
<td>EG-MOHP-99334-GO-RFQ</td>
<td>Sofosbuvir for Qena district.</td>
<td>400mg+60mg</td>
<td>60c</td>
<td>98,700.00</td>
<td>106,185.32</td>
</tr>
</tbody>
</table>

Notes:
- Price (1) and Price (2) are the quoted prices for Sofosbuvir and Daclatasvir, respectively.
- The quantities are in milligrams (mg) and cents (c) for each drug combination.
- Dates indicate the dates of purchase or contract issuance.
<table>
<thead>
<tr>
<th>District</th>
<th>Drugs</th>
<th>RFQ</th>
<th>Daclatasvir</th>
<th>Sofosbuvir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gharbia</td>
<td>currently</td>
<td>through</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giza</td>
<td>used</td>
<td>for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Awal</td>
<td>buying</td>
<td>for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basyon</td>
<td>for</td>
<td>for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smanoud</td>
<td>for</td>
<td>for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zayed</td>
<td>of</td>
<td>of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giza</td>
<td>of</td>
<td>of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gharbia</td>
<td>of</td>
<td>of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Egyptian</td>
<td>for</td>
<td>for</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RFQ Numbers:**

- EG-MOHP-115240-GO-120000
- EG-MOHP-115234-GO-120000
- EG-MOHP-115232-GO-120000
- EG-MOHP-115231-GO-120000
- EG-MOHP-115226-GO-120000

**Drug Doses:**

- Daclatasvir: 60 mg+60 mg+60 mg+60 mg+60 mg
- Sofosbuvir: 12 mg+12 mg+12 mg+12 mg+12 mg

**Price:**

- 98,600.00
- 98,300.00
- 98,200.00
- 99,400.00

**Signatures:**

- 2019-05-19
- 2019-05-24
- 2019-05-25
- 2019-07-24
- 2019-07-25
Governorate are national currently used for treatment. Drugs through RFQ EG-MOHP-115241-GO-EG-MOHP-115451-GO-
EG-MOHP-115449-GO-EG-MOHP-115447-GO- for purchasing.

Elsharqya drugs are national for the treatment of secondary virus. Daclatasvir and Sofosbuvir are used for combination treatment in Kber district. The combination is for 12 weeks of treatment. The virus is treated by IBRD.

Secondary Request for Quotations for the implementation of the program. The process is in Stage 98,700.00 for Implementation and 99,200.00 for 2019-05-27. Additional signature on 2019-07-28.
<table>
<thead>
<tr>
<th>District</th>
<th>State</th>
<th>Product</th>
<th>Quantity</th>
<th>Unit</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shobra</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>El IBRD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tala</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alwasta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safaga</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elqahirah</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koom</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- The table above lists the districts and states where certain products are to be purchased. The columns represent the products, quantities, units, and prices.
- The districts include Shobra, El IBRD, Tala, Alwasta, Safaga, Elqahirah, and Koom.
- The states are not specified for this table.
- The products are not clearly defined but could possibly be medications or other healthcare-related items.
- The quantities are not provided for this table.
- The units are not specified for this table.
- The prices are not provided for this table.

**Additional Information:**
- The table appears to be part of a larger document that outlines a request for quotations (RFQ) for various districts and states.
- The document mentions the purchase of national and international services.
- The table includes various codes and numbers, possibly related to the purchase orders or item numbers.
<table>
<thead>
<tr>
<th>No.</th>
<th>Contract Number</th>
<th>Contract Name</th>
<th>Contract Type</th>
<th>Contract Value</th>
<th>Contract Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>EG-MOHP-94066-GO-RFQ</td>
<td>Planning and Supplies Faiyum</td>
<td>Single</td>
<td>19,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>2</td>
<td>EG-MOHP-94039-GO-RFQ</td>
<td>Planning and Supplies Beheira</td>
<td>Single</td>
<td>23,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>3</td>
<td>EG-MOHP-93915-GO-RFQ</td>
<td>Tablet Damanhour</td>
<td>Single</td>
<td>98,300.00</td>
<td>Signed for Limited Envelope</td>
</tr>
<tr>
<td>4</td>
<td>EG-MOHP-94067-GO-RFQ</td>
<td>Tablet Aswan</td>
<td>Single</td>
<td>97,900.00</td>
<td>Canceled</td>
</tr>
<tr>
<td>5</td>
<td>EG-MOHP-94060-GO-RFQ</td>
<td>Tablet Qena</td>
<td>Single</td>
<td>97,500.00</td>
<td>Canceled</td>
</tr>
<tr>
<td>6</td>
<td>EG-MOHP-134792-GO-RFQ</td>
<td>Tablet Banha</td>
<td>Single</td>
<td>100,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>7</td>
<td>EG-MOHP-123296-GO-RFQ</td>
<td>Tablet Kafr</td>
<td>Single</td>
<td>100,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>8</td>
<td>EG-MOHP-123294-GO-RFQ</td>
<td>Tablet Shabin</td>
<td>Single</td>
<td>100,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>9</td>
<td>EG-MOHP-123289-GO-RFQ</td>
<td>Tablet El Feyy</td>
<td>Single</td>
<td>100,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>10</td>
<td>EG-MOHP-123278-GO-RFQ</td>
<td>Tablet El C</td>
<td>Single</td>
<td>100,000.00</td>
<td>Under Quotations</td>
</tr>
<tr>
<td>11</td>
<td>EG-MOHP-123276-GO-RFQ</td>
<td>Tablet El C</td>
<td>Single</td>
<td>100,000.00</td>
<td>Under Quotations</td>
</tr>
</tbody>
</table>

**Additional Notes:**
- **Activities:** Healthcare, Strengthening Planning and Supplies for Family Planning.
- **Stage:** 2019-01 to 2019-07
- **IBRD 88950:** Limited to 19,000.00.
- **Post Quotations:** Request Envelope - Under Quotations.